Peptide & Tetramer Core Facility

| Mission | Offer | Clients | Instruments | Certification



The Peptide & Tetramer Core Facility (PTCF) is a platform within the Lausanne branch of the Ludwig Institute for Cancer Research (LICR), part of the Department of oncology UNIL CHUV. Its mission is to provide the department as well as researchers worldwide with state-of-the-art, high quality peptides and peptide-MHC (pMHC) based reagents.

PTCF scientists have outstanding expertise in immunology and peptide & protein chemistry with over 30 years of interdisciplinary experience. PTCF high quality reagents acquired a solid worldwide reputation and are referenced in over 200 peer-reviewed publications.



The PTCF offers state of the art peptides and peptide-based services for projects in immunology, vaccines and peptide chemistry. Peptides are available in different scales and different purity grades, suitable for research purposes as well as preclinical studies (Chevalier, Bobisse et al. 2015).

Our pMHC reagents allow isolation and in depth analysis of antigen-specific CD8 and CD4 T cells (Schmidt, Guillaume et al. 2011, Schmidt, Dojcinovic et al. 2013).



Customers of PTCF include scientists in academic research laboratories, large non-profit clinical trials, and pharmaceutical companies. In addition to our local market, PTCF also services customers in the USA, Europe and Japan.  



Peptide synthesis

PTCF has 5 automatized synthesizers. Two CSbio 336 for production up to 1g, 1 high-throughput MultiPep INTAVIS synthesizer that can produce up to 384 peptides and 2 MultiPep RSi dedicated for production of up to 72 “enhanced grade” peptides.

Peptide purification

Peptides are purified on 2 high-throughput HPLC-PREP coupled to single quadrupole mass spectrometers from Agilent Technologies. MS detection allow direct detection of desired peptides.

Peptide QC

Peptide QC are performed on UPLC 6230 coupled to TOF mass spectrometer from Agilent Technologies. Identity of peptides is determined by MS with accuracy of 0.02 da and purity is determined by UV detection at 215 nm.



ISO certification is planned in 2022. PTCF already provides enhanced grade peptides approved as raw material in some phase I clinical trials conducted within the Department of oncology UNIL CHUV.


Follow us:  




Pr George COUKOS

General manager

Harari Lab Schmidt Julien-crop226x257.png


Phone +41 21 692 5982

Ch. des Boveresses 155 - CH-1066 Epalinges
Tel. +41 21 692 59 92
Fax +41 21 692 59 95
Ludwig Cancer ResearchUniversité de LausanneCentre Hospitalier Universitaire Vaudois (CHUV)